On the one hand, in cancer patients, TLR4 (expressed by immunocytes) can mediate activation of innate or adaptive immunity, and could confer benefit, as several reports indicate the potency of TLR agonists in enhancing antitumor immune responses [26]. This evidence concerns the gene TLR4 and cancer.